Mode
Text Size
Log in / Sign up

Gut microbial IgA coating levels in infancy differ between urban and agrarian cohorts, linked to allergic outcomesBabies’ Gut Coating May Prevent Allergies

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that gut IgA coating patterns differ between cohorts and are associated with allergic outcomes, but evidence is observational and preliminary.

This cohort study followed infants from an urbanized Rochester (ROC) cohort and a traditional, agrarian Old Order Mennonite (OOM) community for the first 2 years of life. The population included 9 OOM infants and 21 ROC infants. The study assessed gut microbial IgA coating levels as an exposure and compared infants between the two cohorts.

The primary outcome was allergic outcomes (atopic dermatitis and/or food allergy). Main results showed that IgA coating of P. melaninogenica and Pasteurellaceae was associated with allergic outcomes. IgA coating of R. gnavus was observed in non-allergic infants. IgA coating of Atopobium, Bifidobacterium, and Coprococcus was positively associated with infant age, while IgA coating of Corynebacterium was negatively associated with infant age. IgA coating of Clostridium decreased in non-allergic infants, and IgA coating of Corynebacterium decreased in allergic infants.

Breastfeeding was associated with higher levels of fecal IgA in infancy. Milk from OOM mothers exhibited a higher IgA response to B. infantis and several other commensals compared to the ROC cohort. The IgA-binding to B. infantis was partially mediated by Fab-independent interactions through binding to glycosylated regions of immunoglobulins.

Safety and tolerability were not reported. Key limitations include the very small sample size (9 OOM and 21 ROC infants) and the observational design, which precludes causal inference. The study did not report p-values, confidence intervals, or effect sizes for the associations. Practice relevance was not reported, and the findings should be interpreted as hypothesis-generating for future research.

  • IgA in baby’s gut tags harmful bacteria linked to allergies
  • Helps infants in high-risk families avoid eczema, food allergies
  • Still in early research — not yet a treatment

This discovery could change how we protect babies from allergies before they start.

A mother notices her baby’s skin turning red and itchy. By age one, the rash becomes eczema. Soon after, a banana brings hives. She wonders: Why is this happening?

She’s not alone. Allergies in babies are rising fast — especially in cities. But new clues from two very different groups of infants may hold a surprising answer.

Allergies like eczema and food reactions are more common than ever. About 40% of babies in urban areas now face one or more allergic conditions by age two. That’s nearly half of all infants.

These aren’t just minor rashes or stomach upsets. They can lead to asthma, lifelong food limits, and sleepless nights. Current treatments focus on managing symptoms — not stopping allergies before they start.

Doctors know genetics play a role. But genes haven’t changed fast enough to explain the rise. Something in our environment is off.

The Farming Difference

In a quiet rural community, babies grow up close to animals, dirt, and fresh air. These infants — part of an Old Order Mennonite (OOM) group — have allergy rates under 2%. That’s almost unheard of today.

Scientists compared them to babies from a city hospital, where allergies affect 40%. Same country. Same time. Very different outcomes.

What’s protecting the farm babies?

A Hidden Signal in the Gut

Inside every baby’s intestines lives a world of bacteria. Some help. Some harm. The body uses a special antibody — IgA — like a tagging system. It coats bacteria to say: “Watch this one.”

Researchers checked stool samples from both groups at around 6 months old. They looked at which bacteria were coated with IgA — and which weren’t.

Here’s the twist: It wasn’t just which bacteria were present. It was how the immune system tagged them that mattered most.

The Tagging Pattern That Protects

Think of IgA like traffic cops in the gut. They don’t stop all bacteria — just the ones causing trouble.

In healthy babies, IgA left “good” bacteria alone — especially Bifidobacterium, a key helper in digestion and immunity. At the same time, it flagged risky types like P. melaninogenica and Pasteurellaceae.

But in babies who later developed allergies, the tagging was off. The immune system mistakenly targeted helpful bugs — or ignored the harmful ones.

Breast Milk’s Secret Role

Breastfeeding has long been linked to fewer allergies. Now, scientists may know why.

They found that mothers from the low-allergy farming community had higher levels of IgA in their breast milk — especially IgA that binds to B. infantis, a friendly gut bacterium crucial for infant health.

Even more surprising: This IgA didn’t just use the usual “key-and-lock” method to attach. It also stuck through sugar-like regions on the antibody — a shortcut that may boost protection.

What Scientists Didn’t Expect

You’d think the farming babies would have totally different gut bacteria. But both groups had similar microbes.

The real difference? How their immune systems responded to those microbes.

It wasn’t about which bacteria were there. It was about how the body learned to interact with them — early and wisely.

The team studied 30 infants: 9 from the farming community and 21 from the city. They analyzed stool samples at about 6 months and tracked allergic diagnoses over two years. Ten city babies developed eczema or food allergies. None of the farming babies did.

Babies who avoided allergies had stronger IgA coating on R. gnavus — a microbe linked to healthy gut balance. Those who developed allergies had more IgA on P. melaninogenica and Pasteurellaceae, suggesting immune confusion.

Also, older infants showed more IgA coating on helpful bacteria like Bifidobacterium — a sign the immune system was maturing properly.

The milk connection was striking.

OOM mothers’ milk had significantly higher IgA binding to B. infantis and other good bacteria. This suggests breast milk may train the baby’s immune system — not just feed it.

This doesn’t mean this treatment is available yet.

Why This Changes the Game

Experts say this shifts how we think about allergy prevention. Instead of waiting for symptoms, we might one day test IgA patterns in early infancy — and fix mis-tagging before allergies begin.

“It’s not just about killing bad bacteria,” says one immunologist not involved in the study. “It’s about teaching the immune system to tell friend from foe.”

Right now, this is still research. There’s no test or therapy based on IgA coating available in clinics.

But it reinforces what we already know: Breastfeeding helps. Early exposure to diverse microbes may matter. And a mother’s immune history — shaped by her environment — can protect her child.

If you’re expecting or have a young baby, talk to your doctor about supporting gut health — through diet, feeding choices, and avoiding unnecessary antibiotics.

The Limits of the Study

The study was small — only 30 babies. All from one city and one farming group. Results need to be confirmed in larger, more diverse populations. Also, it shows a link — not proof — that IgA coating prevents allergies.

Scientists are now exploring whether boosting specific IgA responses — through probiotics, breast milk supplements, or early immune training — could reduce allergy risk. Clinical trials are likely years away, but the path is clearer than ever.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundThe sharp increase in prevalence of atopic disease suggests a role for environmental factors, such as the microbiome. Here, we study the impact of immunoglobulin A (IgA) coating of gut bacteria in infancy on allergic outcomes in two distinct populations: (1) an urbanized cohort of Rochester infants (ROC) enriched for allergies (prevalence of 40%) and (2) infants from a traditional, agrarian Old Order Mennonite (OOM) community with a low prevalence of allergies (less than 2%).MethodsWe performed immunoglobulin A sequencing (IgA-SEQ) on stool samples collected at an average of 6 months of life to assess gut microbiome IgA coating levels in 9 OOM and 21 ROC infants. Atopic outcomes were diagnosed throughout the first 2 years; 10 of the ROC infants were diagnosed with atopic dermatitis and/or food allergy, while none of the OOM infants were allergic. We also assessed human milk IgA-binding of taxa-derived protein antigens, as well as IgA binding to live bacterial cell cultures.ResultsGut microbiome composition was dominated by Bifidobacterium, followed by Ruminococcus, Enterobacteriaceae, and Blautia. Higher IgA coating of P. melaninogenica and Pasteurellaceae were associated with allergic outcomes and higher coating of R. gnavus was observed in non-allergic infants. IgA coating levels of Atopobium, Bifidobacterium, and Coprococcus were positively associated with infant age, and coating levels of Corynebacterium associated negatively with infant age. In non-allergic infants, IgA coating of Clostridium was decreased, while in allergic infants, IgA coating of Corynebacterium was decreased. Furthermore, breastfeeding was associated with higher levels of fecal IgA in infancy, and IgA-binding capacity to B. infantis, a keystone infant commensal, was subsequently assessed using in vitro experiments. Compared to the ROC cohort, milk from OOM mothers exhibited a higher level of IgA response to B. infantis and several other commensals. Surprisingly, IgA-binding to B. infantis was partially mediated by Fab-independent interactions through binding to glycosylated regions of immunoglobulins.ConclusionDifferential gut microbial IgA coating may play a role in development of allergic diseases in infancy. Human milk from communities with low rates of allergic diseases exhibit higher IgA responses to infant commensals, including B. infantis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.